Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 4/20 | 0.39 |
| ▸ | PRKCI | P41743 | 2/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30259044 | 0.83 | MAPK1 (0.60) | MAPK1ALDH1A1AXLPRKCIRIPK1 | |
| SCHEMBL650714 | 0.83 | MAPK1 (0.60) | MAPK1ALDH1A1AXLPRKCIRIPK1 | |
| SCHEMBL10141177 | 0.75 | MAPK1 (0.48) | MAPK1AXLPRKCIRIPK1APP | |
| SCHEMBL29699518 | 0.75 | MAPK1 (0.48) | MAPK1AXLRIPK1DYRK1AAPP | |
| SCHEMBL12847281 | 0.75 | MAPK1 (0.71) | MAPK1AXLPRKCIRIPK1APP | |
| SCHEMBL16433147 | 0.72 | ALDH1A1 (0.41) | MAPK1ALDH1A1DYRK1ANUDT1 | |
| SCHEMBL12810052 | 0.71 | MAPK1 (0.44) | MAPK1AXLPRKCIRIPK1APP | |
| SCHEMBL20875000 | 0.71 | MAPK1 (0.46) | MAPK1RIPK1APP | |
| SCHEMBL21025526 | 0.71 | MAPK1 (0.44) | MAPK1AXLPRKCIRIPK1APP | |
| SCHEMBL25523673 | 0.71 | MAPK1 (0.44) | MAPK1AXLPRKCIRIPK1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104093715-B | 4-(benzoimidazol-2-yl)-thiazole compounds and related aza derivatives | 埃科特莱茵药品有限公司 | 2017-04-26 | — | — | CN | claimed |
| EP-4646414-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025231152-A1 | COMPOUNDS AND METHODS FOR RESTORING BETA-ADRENERGIC RECEPTOR FUNCTION | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-06 | — | — | WO | disclosed |
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2025076235-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-07-25 | — | — | US | disclosed |
| WO-2024148091-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-116323566-B | Sulfanone compound and preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PROMIDIS S.R.L. (IT) | 2024-04-04 | — | — | US | disclosed |
| CN-101815712-A | Pyrazole compound and as the purposes of RAF inhibitor | PFIZER | 2010-08-25 | — | — | CN | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109900-A1 | AZABICYCLIC SHP2 INHIBITORS | PTPN22, PTPN2, PTPN5 | MAPK1 489/4885ALDH1A1 3046/4885AXL 1227/4885 |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | MAPK1 189/4885ALDH1A1 4329/4885AXL 3878/4885 |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | MAPK1 150/4885ALDH1A1 615/4885AXL 188/4885 |
| US-20240246969-A1 | HETEROCYCLIC DERIVATIVES AS CAMKK2 INHIBITORS | CAMKK2, CAMKK1, CAMK1 | MAPK1 372/4885ALDH1A1 3614/4885AXL 2723/4885 |
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | MAPK1 1903/4885ALDH1A1 1000/4885AXL 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.